Published in Mod Pathol on March 19, 2010
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut (2011) 2.14
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging (2013) 2.06
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology (2012) 1.86
A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg (2014) 1.76
The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch (2010) 1.42
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology (2016) 1.09
Molecular pathology of pancreatic neuroendocrine tumors. J Gastrointest Oncol (2012) 1.01
[What's new? The 2010 WHO classification for tumours of the pancreas]. Pathologe (2011) 0.99
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel) (2015) 0.98
A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer (2013) 0.97
Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease. World J Surg (2014) 0.95
Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2014) 0.94
Surgical management of pancreatic neuroendocrine tumors. Surg Today (2011) 0.93
Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol (2012) 0.92
Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology. Diagn Cytopathol (2014) 0.92
Concomitant pancreatic endocrine neoplasm and intraductal papillary mucinous neoplasm: a case report and literature review. World J Surg Oncol (2013) 0.91
Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. Eur Radiol (2014) 0.90
Differing Clinical Courses and Prognoses in Patients With Gastric Neuroendocrine Tumors Based on the 2010-WHO Classification Scheme. Medicine (Baltimore) (2015) 0.89
The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg (2011) 0.89
TNM staging of pancreatic neuroendocrine tumors: an observational analysis and comparison by both AJCC and ENETS systems from 1 single institution. Medicine (Baltimore) (2015) 0.86
A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discov (2015) 0.85
Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. Surgery (2011) 0.84
Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases. Virchows Arch (2014) 0.83
Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification. BMC Surg (2015) 0.82
Clinicopathological features and survival analysis of gastroenteropancreatic neuroendocrine neoplasms: a retrospective study in a single center of China. Chin J Cancer Res (2015) 0.82
von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms. Surgery (2012) 0.82
Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines. Cytojournal (2014) 0.82
The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. Virchows Arch (2011) 0.82
Risk factors for aggressive nonfunctional pancreatic neuroendocrine tumors and the role of endoscopic ultrasound guided fine-needle aspiration. Endosc Ultrasound (2016) 0.81
Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors. Chin Med J (Engl) (2015) 0.80
Chromosome 3p alterations in pancreatic endocrine neoplasia. Virchows Arch (2010) 0.80
Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm. J Cancer Res Clin Oncol (2016) 0.79
Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes. J Surg Oncol (2011) 0.79
PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target. Cancer Biol Ther (2015) 0.79
Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors. Virchows Arch (2015) 0.78
Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms - Predictive and Prognostic Markers for Treatment Stratification. PLoS One (2015) 0.78
Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. Medicine (Baltimore) (2015) 0.78
Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. Jpn J Clin Oncol (2015) 0.78
Comparison of the prognostic values of the 2010 WHO classification, AJCC 7th edition, and ENETS classification of gastric neuroendocrine tumors. Medicine (Baltimore) (2016) 0.77
Factors related to long-term survival in patients affected by well-differentiated endocrine tumors of the pancreas. ISRN Surg (2012) 0.77
[The ENETS and UICC TNM classification of neuroendocrine tumors of the gastrointestinal tract and the pancreas: comment]. Pathologe (2010) 0.77
Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors. Horm Cancer (2013) 0.77
Postoperative Complications, In-Hospital Mortality and 5-Year Survival After Surgical Resection for Patients with a Pancreatic Neuroendocrine Tumor: A Systematic Review. World J Surg (2016) 0.77
Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study. Medicine (Baltimore) (2016) 0.77
Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. Eur Radiol (2016) 0.77
Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review. ScientificWorldJournal (2012) 0.76
Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surg (2014) 0.76
[What is new in the pathology of pancreatic neuroendocrine tumors?]. Pathologe (2015) 0.76
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al. Eur J Nucl Med Mol Imaging (2014) 0.75
Prognostic markers in smear preparations for pancreatic endocrine neoplasms: A cytomorphologic study and statistical analysis of 20 potential prognostic features. Cytojournal (2016) 0.75
Pancreatic Aetiology for Massive Upper Gastrointestinal Haemorrhage in Pregnancy. Case Rep Surg (2016) 0.75
FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Oncotarget (2016) 0.75
Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience. Korean J Intern Med (2016) 0.75
High clinical and morphologic response using (90)Y-DOTA-octreotate sequenced with (177)Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2016) 0.75
Differential diagnosis between pancreatic neuroendocrine and solid pseudopapillary neoplasms on endoscopic ultrasound-guided fine-needle aspiration. An immunohistochemical study. Saudi Med J (2016) 0.75
Aace/Ace disease state clinical review: pancreatic neuroendocrine incidentalomas. Endocr Pract (2015) 0.75
Comparative evaluation of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in bronchopulmonary neuroendocrine neoplasms: Issues and prospects. Oncotarget (2016) 0.75
Comparison of relapse-free survival in gastric neuroendocrine carcinoma (WHO grade 3) and gastric carcinoma. Therap Adv Gastroenterol (2017) 0.75
A Single Centre Analysis of Clinical Characteristics and Treatment of Endocrine Pancreatic Tumours. Int J Surg Oncol (2015) 0.75
Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: A 12-year experience from a single center. Oncol Lett (2017) 0.75
Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB (Oxford) (2013) 0.75
Pancreatic neuroendocrine tumors. Intractable Rare Dis Res (2017) 0.75
[Neuroendocrine neoplasms of the distal jejunum and ileum]. Pathologe (2014) 0.75
Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs. BMC Cancer (2017) 0.75
Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Oncotarget (2017) 0.75
Anticancer Effects of Baicalein in Pancreatic Neuroendocrine Tumors In Vitro and In Vivo. Pancreas (2017) 0.75
[Grading of neuroendocrine tumors]. Pathologe (2016) 0.75
Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades. Clin Radiol (2016) 0.75
International network of cancer genome projects. Nature (2010) 20.35
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology (2006) 8.83
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40
Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg (2004) 5.09
Identification of a novel antibody associated with autoimmune pancreatitis. N Engl J Med (2009) 4.48
Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch (2004) 3.04
Early versus late drain removal after standard pancreatic resections: results of a prospective randomized trial. Ann Surg (2010) 3.03
Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology (2007) 2.96
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol (2009) 2.94
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol (2010) 2.69
Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg (2008) 2.45
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
Pancreatic fistula rate after pancreatic resection. The importance of definitions. Dig Surg (2003) 2.26
Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer (2005) 2.24
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging (2013) 2.06
Acute fulminant hepatitis E virus genotype 3e infection: description of the first case in Europe. Scand J Infect Dis (2014) 2.03
Reconstruction by pancreaticojejunostomy versus pancreaticogastrostomy following pancreatectomy: results of a comparative study. Ann Surg (2005) 1.94
Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut (2006) 1.91
Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol (2009) 1.90
Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial. Surgery (2003) 1.84
Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. J Proteome Res (2010) 1.81
Pancreatic resections for cystic neoplasms: from the surgeon's presumption to the pathologist's reality. Surgery (2012) 1.76
Mucinous cystic neoplasms of the liver: a clinicopathological study and comparison with intraductal papillary neoplasms of the bile duct. Mod Pathol (2011) 1.74
Laparoscopic distal pancreatectomy: results on a consecutive series of 58 patients. Ann Surg (2007) 1.69
Parenchyma-sparing resections for pancreatic neoplasms. J Hepatobiliary Pancreat Sci (2009) 1.63
Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab (2013) 1.59
Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections. Arch Surg (2012) 1.58
Autoimmune pancreatitis: differences between the focal and diffuse forms in 87 patients. Am J Gastroenterol (2009) 1.56
Autoimmune pancreatitis: pancreatic and extrapancreatic MR imaging-MR cholangiopancreatography findings at diagnosis, after steroid therapy, and at recurrence. Radiology (2011) 1.55
Laparoscopic rectal resection for severe endometriosis of the mid and low rectum: technique and operative results. Surg Endosc (2011) 1.47
Middle pancreatectomy: indications, short- and long-term operative outcomes. Ann Surg (2007) 1.46
Endocrine neoplasms of the pancreas: pathologic and genetic features. Arch Pathol Lab Med (2009) 1.46
"PancPro" as a tool for selecting families eligible for pancreatic cancer screening: an Italian study of incident cases. Dig Liver Dis (2012) 1.45
Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol (2011) 1.42
Volunteer effect and compromised randomization in the Mayo Project of screening for lung cancer. Eur J Epidemiol (2010) 1.42
Amylase value in drains after pancreatic resection as predictive factor of postoperative pancreatic fistula: results of a prospective study in 137 patients. Ann Surg (2007) 1.41
Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2007) 1.40
Latent celiac disease or low-gluten-containing diet? J Pediatr Gastroenterol Nutr (2002) 1.39
Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. Leuk Lymphoma (2014) 1.39
Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol (2009) 1.38
MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer (2010) 1.38
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta (2007) 1.38
Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol (2014) 1.33
Management of 100 consecutive cases of pancreatic serous cystadenoma: wait for symptoms and see at imaging or vice versa? World J Surg (2003) 1.27
Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Int J Cancer (2014) 1.24
Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. Mod Pathol (2007) 1.23
Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg (2012) 1.22
Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology (2007) 1.21
Evaluation of an indirect immunofluorescence assay for strongyloidiasis as a tool for diagnosis and follow-up. Clin Vaccine Immunol (2006) 1.19
Perioperative and long-term results of laparoscopic spleen-preserving distal pancreatectomy with or without splenic vessels conservation: a retrospective analysis. J Surg Oncol (2011) 1.18
Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer (2012) 1.17
Clinical and biological behavior of pancreatic solid pseudopapillary tumors: report on 31 consecutive patients. J Surg Oncol (2007) 1.15
Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery (2011) 1.15
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology (2009) 1.15
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget (2014) 1.14